Whitehawk Therapeutics, formerly Aadi Bioscience, has repositioned itself as a next-generation antibody-drug conjugate (ADC) company focused on cancer treatment. The company in-licensed three ADC programs from WuXi Biologics targeting tumor markers PTK7, MUC16, and SEZ6. Two programs, HWK-007 and HWK-016, entered Phase I clinical trials earlier this year, while the third, HWK-206, is set to start trials this quarter. This strategic shift highlights Whitehawk's commitment to developing innovative cancer therapies with potential clinical impact.
Whitehawk Therapeutics, Inc. is the subject of this update, with Pluang market data providing context for readers. As of Sep 16, 2026 02:01 WIB, among 91 priced Health-sector US stocks tradable on Pluang, 24 rose and 66 fell. Notable movers include Ascendis Pharma A/S (ASND) at USD 235.61 with a -11.06% change, Adaptive Biotechnologies Corp (ADPT) at USD 27.22 with a +9.85% change, and Illumina, Inc. (ILMN) at USD 222.67 with a +6.94% change.
Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, sugges...
MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...
Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...
BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...
Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. This legal action could impact shareholders of the company, highlighting possible mismanagement or misconduct at the le...
